Table 2.
Distribution of Anticholinergic Burden Score by Phenotype and Difference Between Healthy Control and Phenotype
| % (n) | Cognitive Impairment | Frailty | Cognitive Frailty | Cognitive Impairment | Cognitive Frailty | ||
| ACB | MMSE (n = 298) | CHS (n = 512) | MMSE (n = 223) | Trail A (n = 418) | Trail B (n = 493) | Trail A (n = 267) | Trail B (n = 274) |
| 0 | 47.0% (141) | 51.0% (261) | 42.2% (94) | 57.9% (242) | 62.9% (310) | 50.2% (134) | 55.5% (152) |
| 1 | 23.6% (70) | 22.9% (117) | 25.1% (56) | 20.6% (86) | 20.1% (99) | 22.5% (60) | 21.2% (58) |
| 2 | 14.5% (43) | 11.9% (61) | 16.1% (36) | 10.8% (45) | 7.9% (39) | 13.1% (35) | 9.9% (27) |
| 3 | 10.1% (30) | 8.8% (45) | 11.2% (25) | 6.7% (28) | 5.5% (27) | 8.2% (22) | 7.7% (21) |
| 4 | 2.7% (8) | 3% (16) | 3.1% (7) | 2.4% (10) | 2.4% (12) | 3.4% (9) | 3.6% (10) |
| 5 | 1.0% (3) | 1.4% (7) | 0.9% (2) | 1.0% (4) | 1.0% (5) | 1.5% (4) | 1.8% (5) |
| 6 | 0.7% (2) | 0.8% (4) | 0.9% (2) | 0.5% (2) | 0.2% (1) | 0.7% (2) | 0.4% (1) |
| 9 | 0.3% (1) | 0.2% (1) | 0.4% (1) | 0.2% (1) | (0) | 0.4% (1) | (0) |
| Control | 0[6] | 0[5] | 0[6] | 0[5] | 0[4] | 0[5] | 0[4] |
| Phenotype | 1[9] | 0[9] | 1[9] | 0[9] | 0[6] | 0[9] | 0[6] |
| p-value* | <.001 | <.001 | <.001 | <.001 | .042 | <.001 | <.001 |
Note: ACB = Anticholinergic drug burden; CHS = Cardiovascular Heart Study; MMSE = Mini-Mental State Examination.
*Nonparametric Kruskal–Wallis t test to assess differences among groups; median and maximum quantiles.